Quick Answer
Perspective Therapeutics, Inc. reported Operating Income Loss of -$113.56 million for the year ending 2025.
- Perspective Therapeutics, Inc. showed a decrease of -25.0% in Operating Income Loss from 2024 to 2025.
- This data is from Perspective Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2010: -$634.6 thousand | Q1 2011: -$693.4 thousand | Q3 2011: -$1.10 million | Q4 2011: -$792.1 thousand | Q1 2012: -$762.9 thousand | Q3 2012: -$1.12 million | Q4 2012: -$1.10 million | Q1 2013: -$824.1 thousand | Q3 2013: -$1.23 million | Q4 2013: -$1.04 million | Q1 2014: -$989.0 thousand | Q3 2014: -$1.16 million | Q4 2014: -$1.02 million | Q1 2015: -$1.05 million | Q3 2015: -$1.09 million | Q4 2015: -$1.41 million | Q1 2016: -$1.33 million | Q3 2016: -$1.58 million | Q4 2016: -$1.48 million | Q1 2017: -$1.39 million | Q3 2017: -$1.55 million | Q4 2017: -$1.47 million | Q1 2018: -$1.34 million | Q3 2018: -$1.52 million | Q4 2018: -$1.43 million | Q1 2019: -$1.16 million | Q3 2019: -$836.0 thousand | Q4 2019: -$903.0 thousand | Q1 2020: -$548.0 thousand | Q3 2020: -$714.0 thousand | Q4 2020: -$873.0 thousand | Q1 2021: -$766.0 thousand | Q3 2021: -$2.27 million | Q4 2021: -$1.64 million | Q1 2022: -$1.38 million | Q2 2022: -$2.11 million | Q3 2022: -$4.21 million | Q1 2023: -$9.76 million | Q2 2023: -$9.75 million | Q3 2023: -$9.75 million | Q1 2024: -$13.01 million | Q2 2024: -$14.26 million | Q3 2024: -$18.63 million | Q1 2025: -$21.83 million | Q2 2025: -$24.04 million | Q3 2025: -$27.86 million.
- Over the full 15 years of available data (2012 to 2025), Perspective Therapeutics, Inc.'s Operating Income Loss has declined by 3,056.3%.
- Historical annual values: Fiscal year 2025: -$113.56 million | Fiscal year 2024: -$90.89 million | Fiscal year 2023: -$40.94 million | Fiscal year 2022: -$8.67 million | Fiscal year 2022: -$6.42 million | Fiscal year 2021: -$3.45 million | Fiscal year 2020: -$3.48 million | Fiscal year 2019: -$5.25 million | Fiscal year 2018: -$6.73 million | Fiscal year 2017: -$6.31 million | Fiscal year 2016: -$5.08 million | Fiscal year 2015: -$4.34 million | Fiscal year 2014: -$4.59 million | Fiscal year 2013: -$4.07 million | Fiscal year 2012: -$3.60 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: